Augmented cell survival in eutopic endometrium from women with endometriosis: Expression of c-myc, TGF-beta1 and bax genes by Johnson, M Cecilia et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Reproductive Biology and 
Endocrinology
Open Access Research
Augmented cell survival in eutopic endometrium from women with 
endometriosis: Expression of c-myc, TGF-beta1 and bax genes
M Cecilia Johnson*, Marisa Torres, Alessandra Alves, Ketty Bacallao, 
Ariel Fuentes, Margarita Vega and M Angélica Boric
Address: Institute of Maternal and Child Research, School of Medicine, University of Chile; and San Borja Arriarán Clinical Hospital, Santiago, 
Chile
Email: M Cecilia Johnson* - cjohnson@med.uchile.cl; Marisa Torres - marisatorres2003@yahoo.es; Alessandra Alves - alelopes@mi.cl; 
Ketty Bacallao - kbacallao@yahoo.cl; Ariel Fuentes - fuentes_ariel@hotmail.com; Margarita Vega - mvega@med.uchile.cl; M 
Angélica Boric - mboric@med.uchile.cl
* Corresponding author    
Abstract
Background: Endometriosis is a common gynaecological disorder characterized by the presence of
endometrial tissue outside of the uterus. The fragments in normal menstruation are composed of necrotic
and living cells, which do not survive in ectopic locations because of programmed cell death. The aim of
this study was to evaluate if the balance between cell proliferation and apoptosis is changed in eutopic
endometrium from women with endometriosis throughout the menstrual cycle by studying bax (pro-
apoptotic), c-myc (regulator of cell cycle) and TGF-beta1 (involved in cell differentiation) genes.
Methods: Eutopic endometrium was obtained from: 30 women with endometriosis (32.8 +/- 5 years) and
34 fertile eumenorrheic women (36 +/- 5.3 years). We analyzed apoptosis (TUNEL: DNA fragmentation);
cell proliferation (immunohistochemistry (IHC) for Ki67); c-myc, bax and TGF-beta1 mRNA abundance
(RT-PCR) and TGF-beta1 protein (IHC) in endometrial explants.
Results: Cell proliferation strongly decreased from proliferative to late secretory phases in glands, but
not in stroma, in both endometria. Positive staining in glands and stroma from proliferative endometrium
with endometriosis was 1.9- and 2.2-fold higher than control endometrium, respectively (p < 0.05).
Abundance of c-myc mRNA was 65% higher in proliferative endometrium from endometriosis than normal
tissue (p < 0.05). TGF-beta1 (mRNA and protein) augmented during mid secretory phase in normal
endometrium, effect not observed in endometrium with endometriosis. In normal endometrium, the
percentage of apoptotic epithelial and stromal cells increased more than 30-fold during late secretory
phase. In contrast, in endometrium from endometriosis, not only this increase was not observed, besides
bax mRNA decreased 63% versus normal endometrium (p < 0.05). At once, in early secretory phase,
apoptotic stromal cells increased 10-fold with a concomitant augment of bax mRNA abundance (42%) in
endometria from endometriosis (p < 0.05).
Conclusion: An altered expression of c-myc, TGF-beta1 and bax was observed in eutopic endometrium
from endometriosis, suggesting its participation in the regulation of cell survival in this disease. The
augmented cell viability in eutopic endometrium from these patients as a consequence of a reduction in
cell death by apoptosis, and also an increase in cell proliferation indicates that this condition may facilitate
the invasive feature of the endometrium.
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Introduction
Endometriosis is a common gynaecological disorder, fre-
quently associated with infertility and pelvic pain that
occurs almost exclusively in menstruating women of
reproductive age. Although little is known about its aeti-
ology and pathogenesis, the theory of retrograde menstru-
ation and metaplasia of the mesothelium or peritoneum
and implantation of viable endometrial cells has been
widely accepted [1,2]. The morphology of eutopic
endometrium from women with endometriosis is similar
to normal endometrium, but its physiology and biochem-
istry are different. Recent reports show an abnormal sur-
vival capability at the epithelial and stromal levels of the
eutopic endometrium from patients with endometriosis
that may result in their continuous growth [3,4]
In proliferative phase, the endometrium is characterized
by proliferation of cells from the basal layer that respond
to 17β-estradiol, reaching its maximum at ovulation time
and then, falling due to the effects of progesterone with
marked changes in glandular epithelium and stroma.
Besides steroids, other factors are involved in these proc-
esses. In fact, after the priming of estradiol, the expression
of transforming growth factor beta1 (TGF-β1) is up regu-
lated in human endometrium coincidently with the
increase of plasma progesterone concentration, being
down regulated during progesterone withdrawal. Mash-
burn et al. (1994) [5] reported that the highest concentra-
tion of this cytokine in the stroma was during the
secretory phase and suggested that it may regulate epithe-
lial cell proliferation and differentiation (for revision see
Godkin and Dore, 1998) [6]. In epithelial cell lines, TGF-
β plays a central role in maintaining the homeostasis
through limitation of growth by repression of growth-pro-
moting transcription factors, such as c-Myc [7]. As known,
c-Myc is a transcription regulator that can both activate or
inhibit gene expression in favour of cell proliferation.
It is well established that apoptosis is a temporary physio-
logic process by which tissues eliminate dysfunctional
cells by a regulated mechanism that involves a sequence
of intracellular molecular events including members of
the Bcl-2 family, such as Bax, an inducer of apoptosis. In
human endometrium, Bax is expressed differentially
throughout the menstrual cycle, with an expression
mainly in late phase according to the number of apoptotic
cells detected at the end of the menstrual cycle [8,9].
The aim of the present study was to evaluate whether the
balance between cell proliferation and apoptosis is
changed in eutopic endometrium from women with
endometriosis throughout the menstrual cycle. For this
purpose, we evaluated: cell proliferation by the detection
of Ki67 and c-myc mRNA abundance, apoptosis by DNA
fragmentation detection and bax mRNA abundance, and
the expression of TGF-β1 in eutopic endometrium
obtained from women with and without endometriosis.
Materials and methods
Subjects
Eutopic endometrial tissue was obtained from 30 women
undergoing laparatomy for endometriosis associated with
chronic pelvic pain, severe dysmenorrhea and infertility,
and from 34 eumenorrheic women undergoing laparos-
copy for tubal sterilization. The age of these women was
32.8 ± 5 years; range 23 to 40 years and 36 ± 5.3 years;
range 25 to 43 years, respectively (p < 0.05). Both groups
of patients had normal body mass index (BMI ≤ 25) and
they were without hormonal treatment and at least 3
months without contraceptive pills before surgery. The
endometrial samples were obtained with a Pipelle suction
curette from the corpus of the uterus and washed several
times with ice-cold phosphate buffered saline (PBS) to
remove blood. Each patient signed a written informed
consent and the Institutional Ethic Committee approved
this study.
The endometria were dated according to established crite-
ria [10] by an experienced histopathologist and classified
as proliferative (days 1–14, women without (n = 10) or
with (n = 8) endometriosis) or secretory endometria (days
15–28, women without (n = 24) or with (n = 22) endome-
triosis). For both groups of endometria, the secretory
phase was divided in early (days 15–18, n = 15), mid
(days 19–23, n = 18) and late (days 24–28, n = 13). Once
obtained, the tissue was cut into slices and some pieces
were immediately frozen in liquid nitrogen for mRNA
preparation or placed in 4% formalin/PBS (pH 7.2–7.4)
for histological evaluation, cell death determination and
immunohistochemistry.
Immunohistochemistry of Ki67 and TGF-β1
Sections (4 to 6 µm thick) of human endometrial tissue at
different stages of the menstrual cycle were deparaffinized
in xylol and hydrated gradually through graded alcohols.
The sections for Ki67 detection were incubated in 10
mmol/L citrate buffer (pH 6.0) at 98°C for 20 min. All
slides were quenched in 3% H2O2 for 5 min at room tem-
perature, then blocked with 2% BSA in PBS (w/v) for 1 h
at room temperature. Primary antibodies for Ki67 (1:75,
Dako, Carpinteria, LA) and TGF-β1 (1:1000, CBL 778
clon TB21; Cymbus Biotechnology LTD, Hamts, NF) were
applied to the samples and incubated at 37°C for 2 or 1
h, respectively. Immunodetection was performed by using
the streptavidin-biotin peroxidase system (LSAB 2, Dako),
diaminobenzidine (DAB) as chromogen and counter-
stained with hematoxylin. The immunohistochemical
evaluation of Ki67 and TGF-β1 was determined as the per-
centage of positive stained cells. In all cases, three blindedReproductive Biology and Endocrinology 2005, 3:45 http://www.rbej.com/content/3/1/45
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observers evaluated at least 1,000 cells in one section from
each sample.
RNA preparation, cDNA synthesis, Reverse Transcription-Polymerase 
Chain Reaction
Total RNA was isolated from frozen proliferative and
secretory endometria using RNA-solv Reagent (Omega
Bio-teck, Lilburn, GA) plus glycogen (Chemicon Interna-
tional, Inc., Temecula, CA); then the purified pellet was
resuspended in diethylpyrocarbonate-treated water. Com-
plementary DNA (cDNA) was synthesized from 2 µg of
total RNA digested previously by DNase I (Fermentas AB,
Vilnius, Lithuania) using random primers (Invitrogen,
Carlsbad, CA) and 200 U revertAid H Minus M-MuLV
reverse transcriptase (Fermentas) following the manufac-
turer's instructions.
The amplification of bax mRNA was performed as indi-
cated in Johnson et al. (2004a) [11]; c-myc, and TGF-β1
mRNAs were studied using specific pairs of primers: c-myc
(330 bp), NID: g34815, upstream 5'-GAT TCT CTG CTC
TCC TCG A-3' and downstream 5'-CTC TGA CAC TGT
CCA ACT TG-3'; TGF-β1 (307-bp), NID:gi 10863872,
upstream 5'-CAC CAA CTA TTG CTT CAG C-3' and down-
stream 5'-GAT CAT GTT GGA CAG CTG-3'. Two µl of
cDNA per reaction were adjusted to a total volume of 25
µL by adding PCR buffer containing 3 mmol/L MgCl2,
0.125 U of Taq DNA polymerase (Invitrogen), 0.25
mmol/L nucleotide mix and 0.4 µmol/L of each specific
human primer (Invitrogen). As internal control, 18S rRNA
cDNA [12] was amplified in each sample in the same con-
ditions described above. The reaction was performed in
ThermalCycler PT-100 (MJ Research Inc. Watertown, MA)
at denaturation: 94°C for 45 sec; annealing: 55°C for 60
sec for c-myc, bax and 18S rRNA, or 53°C for TGF-β1;
extension: 72°C for 60 sec, and repeat for 18 cycles for
18S rRNA, 30 cycles for c-myc and 33 cycles for bax and
TGF-β1. To determine that the amplification of all the
genes were within a linear range, we previously evaluated
the linearity of amplification of the corresponding tran-
scripts in human endometria explants and the number of
cycles were then decided.
Amplified fragment products were visualized on a 1.0%
agarose gel using ethidium bromide staining. Semiquan-
tification of PCR-products was performed by image anal-
ysis (Kodak EDAS 290 Electrophoresis Documentation
and Analysis System, Kodak 1D Image Analysis Software,
Rochester, NY), and its identity was confirmed by
sequencing (ABI PRISM model 310 version 3.4 automatic
sequencer; Perkin Elemer cetus, Norwak, CT).
Apoptosis detection system
DNA fragmentation was assessed by TUNEL according to
the specifications of the manufacturer and adapted by us
[13]. Briefly, paraffin tissue sections mounted on silane-
coated slides (4–6 µm thick) were deparaffinized with
xylol, rehydrated and fixed with 4% methanol-free for-
maldehyde/PBS; then deproteinated for 10 min (20 µg/
mL proteinase K in PBS), washed and post-fixed again. To
avoid artificial DNA fragmentation, only nuclease-free
solutions were used during the whole procedure.
The labeling of 3'-OH ends of fragmented DNA was per-
formed by incubation with fluorescein-12-deoxy-UTP
using 12.5 U terminal deoxynucleotidyl transferase (TdT)
for 1 h at 37°C in a humidified chamber. As positive con-
trol, normal endometrium pre-treated with DNase dis-
played nuclear positive reactivity in the majority of cells,
demonstrating the incorporation of the fluorescent nucle-
otide at 3'-OH ends to the fragmented DNA. To estimate
non-specific binding and autofluorescence, negative con-
trols were included in all assays where tissue sections were
incubated without the TdT enzyme. Slides were analyzed
by fluorescence microscopy with a wide-band excitation
barrier filter suitable for analyzing both green (fluorescein
labelled fragmented DNA) and red (propidium iodide
counterstain) fluorescence. Three independent observers
selected different optical fields in a random manner to
determine the percentage of positive staining in at least
1,000 cells for each sample. The assessment of DNA frag-
mentation by the TUNEL analysis has been shown to
detect mainly apoptosis, although positive staining in
necrotic cells cannot be ruled out. Therefore, in this study
we confirmed the presence of morphological apoptosis by
light microscopy and the absence of necrosis was estab-
lished by morphological criteria.
Statistical analysis
Results were expressed as mean ± SEM of the number of
experiments indicated in the figure legends. The age of the
women was expressed as mean ± SD. Data were statisti-
cally analyzed by Student's t-test (age women) or one-way
ANOVA followed by Tukey's Multiple Comparison test
(Tables and Figures). Difference was considered statistical
significant at p less than 0.05.
Results
Cell proliferation
Nuclear immunostaining of Ki67 was detected in the cell
nucleus of both epithelial and stromal compartments dur-
ing the menstrual cycle in eutopic endometrium of
women with or without endometriosis (Figure 1A–D).
Cell proliferation decreased from proliferative to mid and
late secretory phases in the normal epithelial gland of
both endometria (p < 0.05), with no important changes
in the stromal compartment (Table 1). The positive stain-
ing observed in epithelial and stromal proliferative
endometrium obtained from women with endometriosis
was 1.9- and 2.2-fold higher than normal proliferativeReproductive Biology and Endocrinology 2005, 3:45 http://www.rbej.com/content/3/1/45
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endometrium, respectively (p < 0.05). A tendency of
higher cell proliferation was observed in epithelium from
endometriosis than in normal epithelium obtained dur-
ing early and mid secretory phases (Table 1).
Detection of TGF-β1 and c-myc in eutopic endometrium 
obtained from women with and without endometriosis 
during the menstrual cycle
During the menstrual cycle, the mRNA of TGF-β1
increased more than 50% in mid and late secretory phases
in normal endometrium (p < 0.05), effect that was not
detected in eutopic endometrium obtained from women
with endometriosis, remaining unchanged throughout
the cycle (Table 2).
Positive TGF-β1 immunostaining was homogenously dis-
tributed in the cytoplasm of stromal cells, and a weak
intensity was observed in glands of both types of
endometrium (Figure 1E–H). The cytokine was also
detected as secretion in the glands lumen and extracellular
matrix, besides an intense brown staining in blood vessels
and red blood cells (1E and 1H). In normal
endometrium, the highest percentage of TGF-β1 positive
stromal cell was 53 ± 9% at mid secretory phase with an
increase by 2-fold compared to proliferative phase (p <
0.05), whereas no differences were observed in epithelial
cells. In eutopic endometrium from endometriosis, the
percentage of TGF-β1 positive proliferative stromal cells
was similar to normal proliferative stromal cells (28.18 ±
10.6 and 27.3 ± 6.5, respectively) and did not change dur-
ing the menstrual cycle. It was almost undetected in
eutopic endometrium gland from endometriosis.
The abundance of c-myc mRNA was not significantly
changed throughout the menstrual cycle in both types of
endometrium; however, the proto-oncogen was 65%
higher in proliferative endometrium with endometriosis
than normal endometrium, respectively (p < 0.05) (Figure
2).
Immunohistochemical staining for Ki67, TGF-β1 and apoptosis by TUNEL in explants of human endometrium throughout the  menstrual cycle obtained from normal (A, C, E, G, I, J and K) and endometriosis (B, D, F, H and L) women Figure 1
Immunohistochemical staining for Ki67, TGF-β1 and apoptosis by TUNEL in explants of human endometrium throughout the 
menstrual cycle obtained from normal (A, C, E, G, I, J and K) and endometriosis (B, D, F, H and L) women. Representative 
human endometrium explants from (A, B, E, F and I) proliferative phase and (C, D, G, H, J, K and L) secretory phase of the 
menstrual cycle with positive immuno-staining for (A-D) Ki67 and (E-H) TGF-β1 or positive DNA fragmentation by TUNEL (K 
and L). Immunohistochemitry (I) and TUNEL (J) negative controls. Cell nuclei are stained with haematoxylin (immunohisto-
chemitry) or propidium iodine (TUNEL). g: glandular, s: stroma, rc: red blood cell. Magnification, 400×.
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Cell death by apoptosis
DNA fragmentation was strongly detected by TUNEL
mostly in epithelial and stromal cells in normal
endometrium from late secretory phase (Figure 1K), effect
that was not observed in late endometrium from women
with endometriosis (Figure 1L). The percentage of apop-
totic cells in late normal endometrium increase more than
30-fold in both cell compartments compared to prolifera-
tive endometrium (p < 0.05) (Figure 3A and 3B). In pro-
liferative, early and mid secretory endometria, a reduced
number of positive apoptotic cells were detectable in both
groups of women. Interestingly, in early secretory
endometrium from women with endometriosis, the
number of apoptotic cells was increased respect to normal
endometrium by 10-fold in stromal cells (p < 0.05) (Fig-
ure 3A and 3B).
The pro-apoptotic gene bax was amplified in both groups
of endometrium (Figure 4). The abundance of bax mRNA
increased at the end of the menstrual cycle in normal
endometrium. Although no significant difference was
observed in proliferative and mid secretory phases, bax
mRNA increased 42% in early and reduced 63% in late
secretory endometria from women with endometriosis
respect to normal endometrium, respectively (p < 0.05)
coincident to the results obtained for apoptotic index.
Discussion
It is known that eutopic endometrium from women with
endometriosis presents physiological differences with
normal endometrium. In this study we show that eutopic
endometrium from these patients has a significant
increase in cell survival, and alterations on DNA fragmen-
tation and on the expression of factors involved in cell
proliferation, cell differentiation and programmed cell
death induction, such as Ki67, c-myc, TGF-β1 and bax.
In agreement with previous reports and in accordance
with results of light microscopy [10,14,15], our data show
that epithelial cells from normal endometrium exhibit a
higher proliferation rate than stromal cells during prolif-
erative and early secretory phases, stages of the menstrual
cycle regulated mainly by estradiol. Although eutopic
endometrium from patients with endometriosis present a
similar Ki67 distribution throughout the menstrual cycle,
a significant augment of cells into cell cycle compared to
normal endometrium was observed, in accordance with
other investigators [16-18]. Even though Ki67 is expressed
in the cell during M, G1, S and G2 phases of cell cycle and
is absent in resting cells (Go), a good correlation between
Ki67 and mitotic indices has been reported in human
endometrium [19]. In contrast, other groups [4,20] have
reported no differences between normal and eutopic
endometria from women with endometriosis, probably
Table 1: Percentage of Ki67 in human eutopic endometrium obtained from women without and with endometriosis during the 
menstrual cycle.
Normal Endometriosis
Gland Stroma Gland Stroma
Proliferative 12.9 ± 4.2 7.7 ± 2.4 27.3 ± 5.3* 16.9 ± 3.8*
Secretory Early 12.4 ± 5.7 5.3 ± 0.6 26.1 ± 5.2 9.3 ± 2.0
Secretory Mid 0.8 ± 0.1# ° 4.3 ± 0.8 10.8 ± 5.7° 5.7 ± 1.6#
Secretory Late 1.0 ± 0.7# ° 10.9 ± 2.4 1.3 ± 0.9# ° 10.5 ± 3.0
Percentage of positive cells was performed in eutopic endometrium explants obtained from women without (normal) and with endometriosis at 
different stages of the menstrual cycle as indicated in Material and Methods. Results are given as mean ± SEM from: 8 and 7 endometria without and 
with endometriosis in each stage, respectively. *p < 0.05 vs. normal endometrium. #p < 0.05 vs. proliferative phase. °p < 0.05 vs. early secretory 
phase.
PCR amplification from endometrium cDNA of women with- out (Normal) and with endometriosis using primers for c-myc  (330-bp) and 18S rRNA (192-bp) Figure 2
PCR amplification from endometrium cDNA of women with-
out (Normal) and with endometriosis using primers for c-myc 
(330-bp) and 18S rRNA (192-bp). Representative gel is 
shown. Graph illustrates the corresponding amplification rel-
ative to 18S rRNA and the results are given as mean ± SEM 
from: 6 and 6 proliferative (P); 6 and 5 early secretory (ES); 5 
and 4 mid secretory (MS) and 5 and 4 late secretory (LS) 
eutopic endometria obtained from women without and with 
endometriosis, respectively. (-) PCR amplification without 
template. *p < 0.05 vs. normal endometria.
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due to the use of different techniques and the detection of
proliferating cell nuclear antigen (PCNA), a nuclear pro-
tein restricted to S phase.
Several genes involved in cell proliferation, such as the
proto-oncogene c-myc are up-regulated by estradiol in dif-
ferent cell types that include human breast cancer cell line
MCF-7 [21,22], rat hepatocyte [23], and pituitary and
somatolactotrophic cell line GH3 [24]. Little information
is available of the proto-oncogen c-myc  in the
endometrium. The presence of the protein c-Myc in nuclei
and cytoplasm of endometrial glands and nuclei stroma
from eutopic and ectopic endometria has been reported
[25], even though its role in the endometrium is not clear.
In the present investigation, the c-myc mRNA abundance
was not modified throughout the menstrual cycle in both
types of endometria studied, although it was augmented
in eutopic endometrium from women with endometrio-
sis compared to normal women. Several findings suggest
that in endometriosis, ectopic endometrium grows and
regresses in an estrogen-dependent manner. Even more,
eutopic endometrium of women with endometriosis con-
tains not only estradiol receptors, but also P450Arom, the
enzyme that catalyzes the conversion of androgen to
estrogen, provoking an estrogenic micro-environment in
this tissue that may act through intracrine pathways [26-
28]. Therefore, the estrogenic microenvironment could
induce the expression of the transcription factor c-myc and
facilitates cell proliferation in the eutopic endometria in
this disease. This effect may be improved by the reduction
of TGF-β1 detected in the endometrium of these patients,
as probable consequence of the loss of the negative regu-
Percentage of apoptotic cells in epithelial (A) and stromal cell  (B) compartments in human endometrium explants obtained  from normal women and women with endometriosis Figure 3
Percentage of apoptotic cells in epithelial (A) and stromal cell 
(B) compartments in human endometrium explants obtained 
from normal women and women with endometriosis. Histo-
logical sections were evaluated by TUNEL technique (see 
text). The results are given as mean ± SEM from: 5 and 6 
proliferative; 5 and 6 early secretory; 4 and 5 mid secretory; 
7 and 6 late secretory eutopic endometria obtained from 
women without (normal) and with endometriosis, respec-
tively. *p < 0.05 vs. normal endometria. °p < 0.05 vs. early 
secretory phase. #p < 0.05 vs. late secretory phase.
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PCR amplification from endometrium cDNA of women with- out (Normal) and with endometriosis using primers for bax  (334-bp) and 18S rRNA (192-bp) Figure 4
PCR amplification from endometrium cDNA of women with-
out (Normal) and with endometriosis using primers for bax 
(334-bp) and 18S rRNA (192-bp). Representative gel is 
shown. Graph illustrates the corresponding amplification rel-
ative to 18S rRNA (192-bp) and the results are given as mean 
± SEM from 5 and 5 proliferative (P); 6 and 5 early secretory 
(ES); 5 and 6 mid secretory (MS) and 4 late secretory (LS) 
eutopic endometria obtained from women without (normal) 
and with endometriosis, respectively. (-) PCR amplification 
without template. *p < 0.05 vs. normal endometria. #p < 0.05 
vs. proliferative phase.
Table 2: TGF-β1 amplification from endometrium cDNA of 
women without and with endometriosis during the menstrual 
cycle.
Normal Endometriosis
Proliferative 1.12 ± 0.1 0.92 ± 0.2
Secretory Early 0.82 ± 0.2 0.86 ± 0.1
Secretory Mid 1.56 ± 0.2# 1.10 ± 0.1*
Secretory Late 1.49 ± 0.1# 1.05 ± 0.1*
Data correspond to amplification rate relative to 18S rRNA. Results 
are given as mean ± SEM from: 8 and 5 proliferative; 7 and 8 early; 4 
and 8 mid and 4 late secretory endometria obtained from women 
without (normal) and with endometriosis, respectively. *p < 0.05 vs. 
normal endometrium; #p < 0.05 vs. early secretory phase.
0
0.5
1
1.5
Pr ol i f er at i ve Ear l y Mi d La t e
Normal
Endometriosis
B a x
m
R
N
A
/
1 8 S     r R N A





Normal
334-bp
192-bp
Endometriosis
bax
18S rRNA
PE S M S L S PE S M S L S (-)
Secretory
Proliferative Early Late Mid
0
0.5
1
1.5
Pr ol i f er at i ve Ear l y Mi d La t e
Normal
Endometriosis
B a x
m
R
N
A
/
1 8 S     r R N A





Normal
334-bp
192-bp
334-bp
192-bp
Endometriosis
bax
18S rRNA
bax
18S rRNA
PE S M S L S PE S M S L S (-) PE S M S L S PE S M S L S (-)
Secretory
Proliferative Early Late Mid
Secretory
Proliferative Early Late Mid
Secretory Secretory
Proliferative Early Late MidReproductive Biology and Endocrinology 2005, 3:45 http://www.rbej.com/content/3/1/45
Page 7 of 8
(page number not for citation purposes)
lation on P450AROM described in choriocarcinoma cell
line (JEG-3) [29].
On the other hand, TGF-βs are likely candidates to par-
tially mediate the effects of progesterone on the expres-
sion of other proteins, which have been suggested to be
involved in the regulation of endometrial cell prolifera-
tion and differentiation [5,6]. In addition, the cyclic
expression of TGF-β1, mainly observed in stromal cells
during the secretory phase as reported in this study, is in
accord to progesterone receptor location [30]. In several
cell types, TGF-β1 plays a role in maintaining tissue
homeostasis by modulating genes involved in the
arresting of cell cycle including down-regulation of c-Myc
[7,31]. Even more, in rabbit uterine epithelial cells, a coor-
dinated but inverse regulation of cell proliferation and
apoptosis by this cytokine was described [32]. The fact
that the cyclicity of TGF-β1 observed in normal
endometrium was absent in eutopic endometrium from
women with endometriosis indicates an impaired local
production in these patients that may favors the cell pro-
liferation. More studies are required to understand the
complex and strict interactions between these molecules
involved in the deregulation on cell proliferation in the
eutopic endometrium of these women.
Proliferation and apoptosis are important biologic proc-
esses in the endometrium remodeling with cell cycle
changes that take place during the menstrual cycle
[14,33]. In the late secretory phase, and related with a
decrease of endometrial progesterone receptor and
plasma progesterone concentration, cell death by apopto-
sis increases in the functional endometrial layer, and at
the time of menstruation it becomes necrotic and hypoxic
and is shed. In the present investigation, the expected
increase of apoptotic cells during late secretory phase was
not observed in eutopic endometrium from women with
endometriosis. Concomitantly to the absence of apopto-
sis in those endometria, the pro-apoptotic gene bax mRNA
abundance was unchanged during the menstrual cycle, at
difference at the increase exhibited in normal
endometrium, suggesting that the reduction of bax expres-
sion may be a mechanism that could explain the
decreased incidence of apoptosis in endometriosis. In
agreement with these results, recent publications
[3,34,35] also reported the absence of apoptotic cells and
the increase of Bcl-2 and the reduction of Bax expression
in eutopic endometrium from women with endometrio-
sis, although Béliard et al. (2004) [4] were unable to find
these differences between patients with endometriosis
and normal women. Curiously, we detected that both bax
mRNA abundance and apoptotic cells were increased in
early secretory phase in eutopic endometrium from
women with endometriosis but not from normal women.
The implication of this augmented cell death in eutopic
endometrium from the patients needs more studies.
It is well known that menstrual fragments are composed
of both necrotic and living cells, which do not survive in
ectopic locations because of its programmed cell death
[36,37]. The loss of cell death by apoptosis in late secre-
tory phase in these patients seems to be consistent with
cell ectopic survival and implantation of endometrial cells
in the peritoneal cavity, effect that is independent of the
disease stages as it was reported by Dmowski et al. (2001)
[34]. The altered expression of c-myc, TGF-β1 and bax
observed in eutopic endometrium from women with
endometriosis, suggests their participation in the deregu-
lation of the cell survival in this tissue. It is known that the
deregulation of apoptotic signaling can play a primary or
secondary role in various diseases; in fact, an insufficient
apoptosis degree contributes to pathogenic processes
including cancer. The present investigation shows that cell
viability is augmented in eutopic endometrium from
women with endometriosis compared to normal
endometrium, primarily due to a reduction in cell death
by apoptosis, and also, an increase in cell proliferation.
These data strongly suggest that this condition may facili-
tate the invasive character of the endometrium in these
patients. Until now, it is not clear why misplaced endome-
trial cells from healthy women do not implant and do not
develop into endometriotic lesions as occurs in women
that develop endometriosis, indicating that some fac-
tor(s) which facilitate(s) their survival and implantation
may be involved. However, we cannot rule out the possi-
ble presence of endometrium cells that belong to basal
layer, aspect not studied in the present work.
Conclusion
The altered expression of c-myc, TGF-β1 and bax observed
in eutopic endometrium from women with endometrio-
sis, suggests the participation of these molecules in the
regulation of the cell survival in this disease. The aug-
mented cell viability in eutopic endometrium from these
patients as consequence of a reduction in cell death by
apoptosis, and also an increase in cell proliferation indi-
cates that this condition may facilitate the invasive charac-
ter of the endometrium. The estrogenic
microenvironment reported in this tissue in women with
endometriosis may explain this improvement of prolifer-
ation/apoptosis balance.
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